Celecoxib plus topical flurbiprofen patch versus celecoxib alone for symptomatic knee osteoarthritis: a randomized controlled trial

Clicks: 16
ID: 328161
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #238 of 339 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 339 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: Rapid symptom control may facilitate earlier mobility and self-management in symptomatic knee osteoarthritis (KOA), but evidence for combining oral and topical non-steroidal anti-inflammatory drugs (NSAIDs) remains limited. This study aimed to determine whether adding a topical flurbiprofen patch to oral celecoxib provides greater short-term improvements in pain, physical function, quality of life, and patient global assessment than oral celecoxib alone in patients with symptomatic KOA. METHODS: In this open-label randomized controlled trial conducted at a tertiary academic hospital from January 2024 to March 2025, 90 patients with chronic inflammatory symptomatic KOA were randomized 1:1 to receive either oral celecoxib 200 mg once daily or celecoxib plus topical flurbiprofen patch twice daily. Outcomes were assessed at baseline and on days 3, 7, and 14. Primary outcomes were pain severity by visual analog scale (VAS) and functional impairment by WOMAC. Secondary outcomes included quality of life by SF-36 and patient global assessment (PGA). RESULTS: Eighty-nine patients completed the study (45 celecoxib; 44 combination therapy). Baseline characteristics were comparable between groups. Compared with celecoxib alone, combination therapy produced greater early pain relief, with larger VAS reductions on day 3 (3.4 ± 0.9 vs. 2.0 ± 0.8, p < 0.01) and day 7 (3.9 ± 1.0 vs. 3.3 ± 1.0, p = 0.02), but not day 14. WOMAC improvement was greater in the combination group on days 3, 7, and 14 (all p < 0.01). At day 14, SF-36 health domain scores and PGA ratings were also higher with combination therapy. CONCLUSIONS: Adding topical flurbiprofen patch to oral celecoxib provided faster early improvement in pain and function and better short-term patient-reported outcomes in symptomatic KOA. TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR1800014584.
Reference Key
openalex_W7212047436 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kaibo Sun, Min Pu, Huaixian Zhang, Liangtao Bai, Xiaoxiao Wu, Ling Fan, Qinsheng Hu
Are you one of these authors? Claim your profile
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag488
URL
https://doi.org/10.1093/rheumatology/keag488
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.